Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

1. p53-induced RNA-binding protein ZMAT3 inhibits transcription of a hexokinase to suppress mitochondrial respiration in human cancer cells.eLife · 2026
   Article
2. Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026
   Review
3. Thymidylate synthase inhibitory drugs induce p53-dependent pathways differently.PloS one · 2026
   Article
4. Identification of Potential Ferroptosis Biomarkers in Multiple Myeloma via WGCNA and Experiments.Cancer reports (Hoboken, N.J.) · 2026
   Article
5. Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.Cell death and differentiation · 2025
   Article
6. Leveraging the htsFLT01/MiRGD Complex to Enhance Apoptosis and Suppress Angiogenesis in MCF7 Breast Cancer Cells.Iranian journal of medical sciences · 2025
   Article
7. Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery.International journal of molecular sciences · 2025
   Review
8. Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation.eLife · 2025
   Article
9. Prunin: An Emerging Anticancer Flavonoid.International journal of molecular sciences · 2025
   Review
10. Harnessing p53 for targeted cancer therapy: new advances and future directions.Transcription · 2025
    Review
11. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).International journal of molecular medicine · 2025
    Review
12. The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies.Genes · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as